A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Status:
RECRUITING
Trial end date:
2027-10-20
Target enrollment:
Participant gender:
Summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.
The goals of this study are to learn:
* If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day
* About the safety of MK-8527 and if people tolerate it
Phase:
PHASE3
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination